(Total Views: 454)
Posted On: 10/29/2019 8:51:52 PM
Post# of 87402
You are correct I found these 2 articles one from April and one from June.
April 2019,
“Merck’s board didn’t stop there in rewarding Frazier for his loyalty. Because the CEO agreed to stay past age 65, he became ineligible for a pension benefit he would have received had he retired. That benefit was worth $2.5 million, so the board boosted his deferred compensation program by that amount. He can collect the money if he stays until January 2020.”
https://www.fiercepharma.com/pharma/loyalty-p...rement-age
Then I found this in June 2019,
“ But now, Merck is laying the groundwork for his exit, as well as that of its seasoned research and development leader Roger Perlmutter, who is 66. At the same time, sales of Keytruda are beginning to mature, leading some investors to ask where the drug giant’s future growth will come from.”
https://www.google.com/amp/s/www.bloomberg.co...essor-hunt
April 2019,
“Merck’s board didn’t stop there in rewarding Frazier for his loyalty. Because the CEO agreed to stay past age 65, he became ineligible for a pension benefit he would have received had he retired. That benefit was worth $2.5 million, so the board boosted his deferred compensation program by that amount. He can collect the money if he stays until January 2020.”
https://www.fiercepharma.com/pharma/loyalty-p...rement-age
Then I found this in June 2019,
“ But now, Merck is laying the groundwork for his exit, as well as that of its seasoned research and development leader Roger Perlmutter, who is 66. At the same time, sales of Keytruda are beginning to mature, leading some investors to ask where the drug giant’s future growth will come from.”
https://www.google.com/amp/s/www.bloomberg.co...essor-hunt
(2)
(0)
